Journal of Veterinary Internal Medicine · 2004 · 78 citations · 18 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyPharmacokinetics Of Anticancer AgentsChemotherapy Toxicity ManagementDose Adjustment In OncologyPharmacokinetics Of Anticancer DrugsToxicity ManagementVeterinary ChemotherapyAnticancer ChemotherapyAntineoplastic Drug TherapyCanine OsteosarcomaChemotherapy Drug AllergyChemotherapy Response AssessmentDrug Hypersensitivity ReactionsOncology Chemotherapy DosingPartial Response Assessment
Paclitaxel (Taxol) was administered to 25 dogs with histologically confirmed malignant tumors at a dosage of 165 mg/m2 i.v. over 3-6 hours every 3 weeks. Dogs received premedication with antihistimines and corticosteroids to reduce hypersensitivity reactions. However, 64% of the dogs still experienced allergic reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant histiocytosis [1 dog]) for a median duration of 53 days. The overall toxicity was unacceptable at the 165 mg/m2 dose. Therefore, subsequent evaluations of paclitaxel in tumor-bearing dogs should a starting dose of 132 mg/m2 i.v. every 3 weeks.
18
Promotion of microtubule assembly in vitro by taxol
Peter B. Schiff, Jane Fant, Susan Band Horwitz · Nature · 1979 · 3.6K citations
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky Ek, Eisenhauer Ea, Arbuck Sg et al. · PubMed · 1993 · 698 citations
Pharmacy, Pharmacology, Toxicology +12
Phase I clinical and pharmacokinetic study of taxol.
Peter H. Wiernik, Edward L. Schwartz, J Strauman et al. · PubMed · 1987 · 454 citations
Pharmacy, Oncology, Pharmacology +14
Cardiac disturbances during the administration of taxol.
Eric K. Rowinsky, William P. McGuire, Thomas Guarnieri et al. · Journal of Clinical Oncology · 1991 · 396 citations
Medicine, Oncology, Pharmacology +12